Harbor Investment Advisory LLC Invests $52,000 in RxSight, Inc. (NASDAQ:RXST)

Harbor Investment Advisory LLC acquired a new position in shares of RxSight, Inc. (NASDAQ:RXST) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 1,502 shares of the company’s stock, valued at approximately $52,000.

Other large investors have also modified their holdings of the company. Geode Capital Management LLC boosted its stake in shares of RxSight by 17.7% during the 3rd quarter. Geode Capital Management LLC now owns 817,117 shares of the company’s stock worth $40,398,000 after acquiring an additional 122,775 shares in the last quarter. Victory Capital Management Inc. boosted its stake in shares of RxSight by 21.0% during the 3rd quarter. Victory Capital Management Inc. now owns 259,864 shares of the company’s stock worth $12,845,000 after acquiring an additional 45,161 shares in the last quarter. Algert Global LLC bought a new stake in shares of RxSight during the 2nd quarter worth $2,488,000. Baillie Gifford & Co. boosted its stake in shares of RxSight by 17.0% during the 3rd quarter. Baillie Gifford & Co. now owns 419,004 shares of the company’s stock worth $20,711,000 after acquiring an additional 60,789 shares in the last quarter. Finally, Barclays PLC boosted its stake in shares of RxSight by 389.8% during the 3rd quarter. Barclays PLC now owns 58,786 shares of the company’s stock worth $2,906,000 after acquiring an additional 46,783 shares in the last quarter. 78.78% of the stock is owned by institutional investors.

RxSight Trading Up 3.0 %

RXST opened at $31.91 on Thursday. The stock has a market cap of $1.29 billion, a price-to-earnings ratio of -38.45 and a beta of 1.20. RxSight, Inc. has a 1 year low of $26.29 and a 1 year high of $66.54. The stock has a fifty day moving average price of $38.10 and a 200 day moving average price of $46.15.

RxSight (NASDAQ:RXST) last posted its earnings results on Thursday, November 7th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.18). RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. The company had revenue of $35.31 million for the quarter, compared to the consensus estimate of $35.15 million. During the same quarter last year, the business earned ($0.35) earnings per share. As a group, sell-side analysts forecast that RxSight, Inc. will post -0.7 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

RXST has been the subject of several recent analyst reports. Stifel Nicolaus decreased their target price on RxSight from $40.00 to $35.00 and set a “hold” rating for the company in a research report on Monday, January 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $66.00 target price on shares of RxSight in a research report on Monday, January 13th. Jefferies Financial Group initiated coverage on RxSight in a research report on Tuesday, October 29th. They issued a “buy” rating and a $72.00 target price for the company. UBS Group initiated coverage on RxSight in a research report on Friday, December 6th. They issued a “buy” rating and a $52.00 target price for the company. Finally, Wells Fargo & Company decreased their target price on RxSight from $42.00 to $40.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, RxSight presently has a consensus rating of “Moderate Buy” and an average price target of $58.13.

Insider Buying and Selling at RxSight

In other RxSight news, insider Ilya Goldshleger sold 3,105 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $51.91, for a total transaction of $161,180.55. Following the transaction, the insider now directly owns 42,246 shares in the company, valued at $2,192,989.86. This trade represents a 6.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Shweta Maniar sold 3,782 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $45.88, for a total value of $173,518.16. Following the transaction, the director now owns 10,902 shares in the company, valued at approximately $500,183.76. This trade represents a 25.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 31,697 shares of company stock worth $1,495,941 over the last three months. Corporate insiders own 9.36% of the company’s stock.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.